PolarityTE Inc

PolarityTE, Inc. is a biotechnology company developing and commercializing regenerative tissue products and biomaterials. The firm products include SkinTE Cryo, SkinTE POC, PTE 11000, OsteoTE and Real Time Assistant. Its SkinTE product is commercially available for the repair, reconstruction, replacement, and supplementation of skin in patients who have a need for treatment of acute or chronic wounds, burns, surgical reconstruction events, scar revision, or removal of dysfunctional skin grafts. The firm operates through the following segments: regenerative medicine products and contract services. PolarityTE was founded on May 8, 1998 and is headquartered in Salt Lake City, UT.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

RegenETP, Inc. is a biotechnology company developing and commercializing regenerative tissue products and biomaterials. The firm's products include SkinTE Cryo, SkinTE POC, PTE 11000, OsteoTE and Real Time Assistant. Its SkinTE product is commercially available for the repair, reconstruction, replacement, and supplementation of skin in patients who have a need for treatment of acute or chronic wounds, burns, surgical reconstruction events, scar revision, or removal of dysfunctional skin grafts. The firm operates through the following segments: regenerative medicine products and contract services. It was founded on May 8, 1998 and is headquartered in Salt Lake City, UT.

PolarityTE Inc (NASDAQ: PTE) shares are surging Tuesday as traders circle bullish commentary from a popular trader in the "FinTwit" community. "FinTwit" is an abbreviated term for "Financial Twitter," which consists of the community of traders and.

Why Is PolarityTE Stock Up 85% Today?

Actinium Pharmaceuticals

Lixte Biotech

Qualigen Therapeutics

Biotech stocks are up today amid an influx of positive news. Here's what investors need to know as these small companies skyrocket.

Biotech Stocks News: What's Going on With LIXT, PTE, QLGN and ATNM Stocks Today?

BioCardia Inc.

Here's what you need to know about buying penny stocks on April 12th The post Top Penny Stocks to Buy? 3 As Stock Futures Climb Before Market Open appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Top Penny Stocks to Buy? 3 As Stock Futures Climb Before Market Open

Phio Pharmaceuticals Corp

Transocean

Check these three penny stocks out as PHIO stock climbs The post 3 Penny Stocks to Watch as Phio Pharma (PHIO) Explodes  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

3 Penny Stocks to Watch as Phio Pharma (PHIO) Explodes

PolarityTE, Inc. (PTE) CEO Richard Hague on Q4 2021 Results - Earnings Call Transcript

PolarityTE to host conference call and webcast today, March 30, 2022, at 8:30 a.m. ET SALT LAKE CITY , March 30, 2022 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE) a biotechnology company developing regenerative tissue products and biomaterials, today provided a business update and reported financial results for the twelve-month period ended December 31, 2021.

PolarityTE Reports Fiscal Year 2021 Financial Results and Provides Business Update

SALT LAKE CITY, March 16, 2022 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE) ("PolarityTE" or the "Company"), a biotechnology company developing regenerative tissue products and biomaterials, today announced that it has closed its previously announced registered direct offering with a single healthcare-focused institutional investor to sell 3,000.000435 shares of Series A convertible preferred stock and 2,000.00029 shares of Series B convertible preferred stock and warrants to purchase up to an aggregate of 16,393,445 shares of common stock. Each share of Series A and Series B preferred stock has a stated value of $1,000 per share and a conversion price of $0.305 per share.

PolarityTE Announces Closing of $5.0 Million Registered Direct Offering

SALT LAKE CITY, March 16, 2022 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE) ("PolarityTE" or the "Company"), a biotechnology company developing regenerative tissue products and biomaterials, today announced that it has entered into a securities purchase agreement with a single healthcare-focused institutional investor to sell 3,000.000435 shares of Series A convertible preferred stock and 2,000.00029 shares of Series B convertible preferred stock and warrants to purchase up to an aggregate of 16,393,445 shares of common stock. Each share of Series A and Series B preferred stock has a stated value of $1,000 per share and a conversion price of $0.305 per share.

PolarityTE Announces $5.0 Million Registered Direct Offering

SALT LAKE CITY, March 10, 2022 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE) today announced that it will report results for the year ended December 31, 2021, by press release on Wednesday, March 30, 2022, at approximately 7:30 a.m. Eastern Time.

PolarityTE to Report Fiscal Year 2021 Financial Results on March 30, 2022

PolarityTE Inc (NASDAQ: PTE) has announced results from a multi-center randomized controlled trial evaluating SkinTE for Venous Leg Ulcers (VLU). There were twenty-nine participants, with 14 receiving SkinTE plus standard of care (SOC) and 15 receiving SOC alone.

PolarityTE's SkinTE Meets Primary, Secondary Goals In Venous Leg Ulcers Trial

SALT LAKE CITY, Feb. 17, 2022 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing regenerative tissue products and biomaterials, today announced the U.S. Patent and Trademark Office (USPTO) recently issued a Notice of Allowance for U.S. Application No. 17/326,734 filed on May 21, 2021.

PolarityTE Announces Allowance of Fourth U.S. Patent

PolarityTE (PTE) announces removal of clinical hold on a proposed pivotal study to evaluate its SkinTE for chronic cutaneous ulcers. PolarityTE plans to start enrollment in the next few months.

PolarityTE (PTE) Gets FDA Nod to Begin Pivotal Ulcer Study

The FDA has signed off PolarityTE Inc's (NASDAQ: PTE) investigational new drug (IND) application to evaluate SkinTE to treat chronic cutaneous ulcers.  This follows the Company satisfactorily addressing clinical hold items that the FDA had previously identified.

FDA Approves PolarityTE's Phase 3 Study Of SkinTE In Chronic Cutaneous Ulcer

SALT LAKE CITY, Jan. 18, 2022 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing regenerative tissue products and biomaterials, today announced that the U.S. Food and Drug Administration (FDA) has approved its investigational new drug (IND) application for the evaluation of SkinTE for the treatment of chronic cutaneous ulcers. This follows the Company satisfactorily addressing clinical hold items that the FDA had previously identified.

PolarityTE Announces U.S. FDA Approval of IND for Pivotal Phase 3 Study of SkinTE® to Support Chronic Cutaneous Ulcer Indication

Armstrong Flooring

Applied UV

BlueCity Holdings Limited

Creative Medical Technology Holdings

Genprex

Eco Wave Power Global AB

We're diving into the top penny stocks to watch today as several names in the space see major movement on Monday alongside heavy trading. The post 8 Top Penny Stocks to Watch Today: EVGRF, PTE, BLCT, GNPX, AFI, CELZ, AUVI, WAVE appeared first on InvestorPlace.

8 Top Penny Stocks to Watch Today: EVGRF, PTE, BLCT, GNPX, AFI, CELZ, AUVI, WAVE

Immix Biopharma

Are these penny stocks on your watchlist right now? The post Best Penny Stocks to Buy Today?

Best Penny Stocks to Buy Today? 3 For Your Watchlist in January

The stock price of PolarityTE Inc (NASDAQ: PTE) increased by 11.49% in the previous trading session. This is why it happened.

PolarityTE Stock (PTE): Why The Price Jumped

SALT LAKE CITY, Dec. 20, 2021 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE) a biotechnology company developing regenerative tissue products and biomaterials, today announced that it has submitted its complete response to the U.S. Food and Drug Administration's (FDA) clinical hold correspondence regarding its Investigational New Drug (IND) Application for SkinTE® with a proposed indication for chronic cutaneous ulcers.  As previously disclosed, the primary hold issues are certain Chemistry, Manufacturing, and Control (CMC) items, including the assay to demonstrate the potency of SkinTE.

PolarityTE Announces Submission of Complete Response to FDA's Clinical Hold Correspondence for SkinTE® Investigational New Drug Application

NEW YORK--(BUSINESS WIRE)-- #PTE--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against PolarityTE, Inc. (NASDAQ: PTE) on behalf of long-term stockholders following a class action complaint that was filed against PolarityTE on September 24, 2021. Our investigation concerns whether the board of directors of PolarityTE have breached their fiduciary duties to the company. The complaint alleges that, throughout the Class Period, Def

POLARITYTE ALERT: Bragar Eagel & Squire, P.C. is Investigating PolarityTE, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

NEW YORK--(BUSINESS WIRE)--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against PolarityTE, Inc. (“PolarityTE” or the “Company”) (NASDAQ: PTE) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired PolarityTE securities between April 30, 2020 and August 23, 2021, inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm's site: www.bgandg.c

Last Few Hours to Actively Participate in PolarityTE, Inc. Class Action: Bronstein, Gewirtz & Grossman, LLC

New York, New York--(Newsfile Corp. - November 23, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of PolarityTE, Inc. (NASDAQ: PTE) between April 30, 2020 and August 23, 2021, inclusive (the "Class Period"), of the important November 23, 2021 lead plaintiff deadline. SO WHAT: If you purchased PolarityTE securities during the Class Period you may be entitled to compensation without payment of any out of pocket...

PTE Final Deadline Today: Rosen, Trusted Investor Counsel, Encourages PolarityTE, Inc. Investors with Losses to Secure Counsel Before Important November 23 Deadline in Securities Class Action - PTE

Los Angeles, California--(Newsfile Corp. - November 22, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against PolarityTE, Inc. ("PolarityTE" or "the Company") (NASDAQ: PTE) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between April 30, 2020 and August 23, 2021, inclusive (the...

UPCOMING DEADLINE REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against PolarityTE, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

New York, New York--(Newsfile Corp. - November 21, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of PolarityTE, Inc. (NASDAQ: PTE) between April 30, 2020 and August 23, 2021, inclusive (the "Class Period"), of the important November 23, 2021 lead plaintiff deadline.SO WHAT: If you purchased PolarityTE securities during the Class Period you may be entitled to compensation without payment of any out of pocket...

PTE FINAL DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages PolarityTE, Inc. Investors With Losses to Secure Counsel Before Important Tuesday Deadline in Securities Class Action - PTE

NEW YORK, Nov. 19, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of PolarityTE, Inc. (NASDAQ: PTE) between April 30, 2020 and August 23, 2021, inclusive (the "Class Period"), of the important November 23, 2021 lead plaintiff deadline. SO WHAT: If you purchased PolarityTE securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

PTE FINAL DEADLINE TUESDAY: ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages PolarityTE, Inc. Investors to Secure Counsel Before Important November 23 Deadline in Securities Class Action - PTE

Los Angeles, California--(Newsfile Corp. - November 19, 2021) -  The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against PolarityTE, Inc. ("PolarityTE" or "the Company") (NASDAQ: PTE) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between April 30, 2020 and August 23, 2021, inclusive (the...

DEADLINE TUESDAY REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against PolarityTE, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

News for PolarityTE Inc Stock (PTE)